Alexander Perl

31PUBLICATIONS
145CO-AUTHORS
Gene and molecular therapyCardiovascular medicine and haematology not elsewhere classifiedMolecular targetsQuantum optics and quantum optomechanicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|Aug 20, 2026
NRAS knockdown reverses monocytic cell state and resensitizes resistant FLT3-AML cells to gilteritinib.

|Jul 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

|Jun 01, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Oct 06, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Mark J Levis, Harry P Erba, Pau Montesinos

|Jul 01, 2025
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Mark J Levis, Mehdi Hamadani, Brent R Logan

Pageof 6

Frequent Collaborators

12 joint publications

Mark Levis

8 joint publications

Mark R Litzow

7 joint publications

Jason Hill

6 joint publications

Hee-Je Kim